Analyst Has 3 Biotech Stocks to Buy With Over 100% Upside Potential
The company also markets DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a life-threatening complication of lymphoma, a cancer of the immune system. Its development pipeline comprises DepoMeloxicam, a long-acting non-steroidal anti-inflammatory drug, which is in preclinical development for the treatment of acute postsurgical pain, and DepoTranexamic Acid, a pre-clinical development product for the treatment or prevention of excessive blood loss during surgery by promoting hemostasis.
The Wedbush team note that the company still has a since rescinded FDA warning letter pall hanging over the stock, but they think that the new promotional strategy for Exparel will yield solid results. The firm noted in a recent report:
We remain optimistic that the additional commercial effort being made including the combination of Pacira increasing its salesforce to 120 and training them on the new and expanded EXPAREL label are likely to continue to gradually increase sales growth. We anticipate an additional sales catalyst in Q3 with launch of EXPAREL for oral and maxillofacial procedures following introduction of a smaller EXPAREL configuration at AAOMS; however, the third quarter is historically a seasonally slow quarter.
Wedbush has a stunning $109 price target for the stock, while the consensus target is $70.78. Both are well above Wednesday’s close at $36.81, after a drop almost 9% on the day.
The Wedbush team is also very positive on this large cap company. United Therapeutics Corp. (NASDAQ: UTHR) develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide.
The company’s principal therapeutic products and product candidates include Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH); Tyvaso, an inhaled prostacyclin therapy for PAH; Adcirca, a once-daily oral therapy for PAH; Orenitram, a prostacyclin analog for PAH; Unituxin, an antibody that binds to cancerous tumors and destroys the cancer cells; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases.
Wedbush highlights the FREEDOM-EV and BEAT enrollment this year, with data to follow in 2017, and the potential new drug application (NDA) approval for a Remodulin implantable pump next year as top catalysts for this outstanding company.
The Wedbush price target is a huge $229. The consensus target is much lower at $129.80, and note that the shares closed near that level on Wednesday at $122.37.
Three big opportunities for aggressive investors. There are also substantial risks, should the outcomes not play out favorably. With that in mind, some smaller speculative positions could be the right play for aggressive, risk-tolerant accounts.